AUTL:NSD-Autolus Therapeutics plc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 6.29

Change

0.00 (0.00)%

Market Cap

USD 0.46B

Volume

0.24M

Avg Analyst Target

USD 15.00 (+138.47%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 and AUTO8 for the treatment of multiple myeloma; AUTO1/22 for the treatment of dual-targeting CAR-T; AUTO3NG for the treatment of hematological cancer; AUTO4 and AUTO5 for T cell lymphoma; AUTO6NG for the treatment of programmed T cell therapies; AUTO6 for the treatment of neuroblastoma; and AUTO7 for the treatment of prostate cancer. Autolus Therapeutics plc was founded in 2014 and is headquartered in London, the United Kingdom. Address: Forest House, London, United Kingdom, W12 7RZ

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

N/A

USD173.62B 50.82 41.56
BNTX BioNTech SE

N/A

USD80.87B 18.39 15.10
REGN Regeneron Pharmaceuticals Inc

N/A

USD68.33B 11.54 8.91
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD47.63B 24.21 16.63
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

N/A

USD35.82B N/A N/A
SGEN Seagen Inc

N/A

USD29.35B 50.34 39.11
GMAB Genmab A/S

N/A

USD28.40B 72.63 8.17
RPRX Royalty Pharma plc

N/A

USD22.53B 30.04 12.50
ALNY Alnylam Pharmaceuticals Inc

N/A

USD22.27B N/A N/A

ETFs Containing AUTL

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -29.64% 31% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -29.64% 31% F 15% F
Trailing 12 Months  
Capital Gain -50.74% 13% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -50.74% 13% F 5% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -25.85% 7% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -25.85% 7% F 2% F
Risk Return Profile  
Volatility (Standard Deviation) 30.29% 86% B 60% D-
Risk Adjusted Return -85.34% 5% F 2% F
Market Capitalization 0.46B 57% F 51% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.64 84% B 67% D+
Price / Cash Flow Ratio -3.89 31% F 62% D-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -54.04% 52% F 27% F
Return on Invested Capital -61.94% 38% F 13% F
Return on Assets -32.55% 33% F 10% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.44 79% C+ 71% C-
Short Percent 4.41% 56% F 38% F
Beta 1.71 30% F 21% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector